

Hypercoagulation and Antiphospholipid Antibody Profile Changes LAB3412 and LAB5034

Effective 5/28/2025

To comply with recommended antiphospholipid syndrome (APS) guidelines to test using ELISA methodology, TriHealth laboratories will begin sending Anticardiolipin Antibodies IgG IgM (LAB3059) and B2Glycoprotein 1 IgG IgM (LAB3118) to ARUP laboratories. This change will impact how hypercoagulation profiles containing these tests are ordered.

The following profiles have been created to replace LAB3412 and LAB5034

508505: Inpatient Hypercoag Profile with Cardiolipin & B2Glycoprotein Antibodies

508506: Inpatient APA Profile with Cardiolipin & B2Glyoprotein Antibodies

508507: Ambulatory Hypercoag Profile with Cardiolipin & B2Glycoprotein Antibodies

508617: Ambulatory APA Profile with Cardiolipin & B2Glyoprotein Antibodies

ELISA Result Units

B2Glycoprotein 1, IgG Antibody
B2Glycoprotein 1, IgM Antibody
Cardiolipin Antibody IgG
Cardiolipin Antibody IgM

MPL

Specimen Preparation

Yellow Serum Separator tube: mix well, allow to clot for 30 minutes, then centrifuge ASAP

References

- 1. Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol 2023; 75:1687.
- 2. UpToDate

Anticardiolipin antibody (aCL) and anti-beta2-glycoprotein I antibody (anti-beta2GPI) thresholds of *moderate* (40 to 79 units) and *high* (≥80 units) should be determined based on standardized enzyme-linked immunosorbent assay (ELISA) results, **not** based on other testing modalities such as new automated platforms with variations of the solid phase (eg, magnetic microparticles and microspheres) and various detection systems (eg, chemiluminescent immunoassay [CLIA], multiplex flow immunoassay [MFI], or flow cytometry).

Inquiries can be directed to:

Sajini Mathew MD, TriHealth Laboratories Medical Director, at sajini mathew@trihealth.com